Navigation Links
CHOP-Zevalin(R) Investigational Regimen Produces 95% Complete Remission and 75% Estimated Two Year Progression-Free Survival in Elderly Patients with Diffuse Large B-cell Lymphoma
Date:3/5/2008

European phase II study of 20 patients reported in Annals of Oncology

SEATTLE, March 5 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq: CTIC; MTA) today announced the publication, by two European institutions, of results of a limited phase II study of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine, and prednisone) followed by administration of Zevalin(R) (Ibritumomab Tiuxetan) in elderly patients (60 years of age or older) with previously untreated diffuse large B-cell lymphoma (DLBCL). In this study, 20 previously untreated elderly patients were treated with a novel combination of six cycles of CHOP chemotherapy followed by Zevalin given six to ten weeks later. The study, which had an overall response rate (ORR) of 100 percent, including a 95 percent complete remission (CR) rate, indicated the efficacy, tolerability, and feasibility of this regimen for these patients. Results of the study were reported in the online edition of February 2008 Annals of Oncology. CTI acquired the U.S. rights to Zevalin in December, 2007.

"Although a small phase II experience, these results in elderly lymphoma patients treated with Zevalin following CHOP without rituximab demonstrate high rates of complete remissions and overall survival and are consistent with the potential to use Zevalin as consolidation therapy in aggressive lymphoma," noted Jack W. Singer, M.D., Chief Medical Officer of CTI. "We continue to be impressed with the high rate of conversion of partial to complete remissions following Zevalin consolidation irrespective of whether or not rituximab therapy is utilized. This publication demonstrates this in elderly patients with DLBCL while similar data in indolent lymphomas were reported at ASH 2007 fr
'/>"/>

SOURCE Cell Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Velcura Therapeutics, Inc. Can Begin Clinical Trials Following Successful Investigational New Drug Application to U.S. FDA
2. Daiichi Sankyo, Lilly Submit New Drug Application for Investigational Antiplatelet Drug, Prasugrel, with U.S. Food and Drug Administration
3. New Drug Application for Tolvaptan, Otsukas Investigational Novel Oral Treatment for Worsening Heart Failure and Hyponatremia, Accepted by the U.S. Food and Drug Administration
4. Lexicon Files Investigational New Drug Application for LX1032 as a Potential Treatment for Carcinoid Syndrome
5. UCB Announces New Data Showing Investigational Drug Lacosamide Significantly Reduced Seizures in Refractory Epilepsy Patients
6. Survival Data Presented From Phase II Study of Investigational Drug ZD4054 in Hormone-Resistant Prostate Cancer Patients
7. Sanofi Pasteurs Investigational H5N1 Influenza Vaccine Achieves High Immune Response at low Dosage
8. FDA Grants Orphan Drug Designation to TREANDA, an Investigational Treatment for Chronic Lymphocytic Leukemia
9. Lexicon Presents Class of Compounds Modulating TPH1, the Target for its LX1031 Investigational Drug for Irritable Bowel Syndrome
10. Tom Shaws NFL Training Center Chooses SURGEX(TM) as Their Exclusive Post Training Nutritional Regimen
11. Anthrax vaccine produces immunity with nanoparticles, not needles
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/26/2014)... Sept. 26, 2014 China Cord Blood Corporation (NYSE: ... leading provider of cord blood collection, laboratory testing, hematopoietic stem cell ... will hold its 2014 annual general meeting of shareholders at its ... China Tower, 1 Garden Road, Central, Hong Kong ... (8:00 a.m. U.S. Eastern Time on December 11, 2014). ...
(Date:9/26/2014)... September 26, 2014 Molecular Biology ... the cell for the regulation of cellular activity and ... interactions between genes and with its environment within the ... of new and novel therapeutic methodologies for the diagnosis, ... , On this occasion, Dr. Srinubabu Gedela, MD of ...
(Date:9/26/2014)... “Inflamax’s Clinical Data Management group is a ... this allows us to support our group in maintaining ... Johnson, Director of Data Management at Inflamax. “Being ... our Clinical Data Managers have been certified by passing ... to offering only the best services to our clients, ...
(Date:9/25/2014)... implicated in several cancers appears to play a pivotal role ... to a new study by NYU Langone Medical Center scientists. ... . , Stem cells are the perpetual adolescents of the ... can be programmed to differentiate into any mature cell type, ... understanding of their biology, however, is needed. ...
Breaking Biology Technology:China Cord Blood Corporation to Hold Annual General Meeting in Hong Kong on December 11, 2014 2Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 2Understanding Genetics and Molecular Biology to Avert Dreadful Medical Challenges during Open Access Week 3NYU Langone scientists identify key factor that maintains stem cell identity 2
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:,ONC, NASDAQ: ONCY) ... research group at The Institute of Cancer Research, ... combination treatment schedules,of reovirus and radiation in human ... The paper, entitled "Enhanced In vitro and In ...
... environment and holding it indefinitely in molecular-sized containers has been ... say it represents a novel method of gas storage that ... safely and efficiently. , This is a proof of concept ... just improving on a method that already exists, said U ...
... the economy is not,only heading towards a recession but ... during January. However, biotech held steady,with the Burrill Biotech ... posted a January loss of 9.9%, and the Dow, ... ride out extremely volatile capital,markets with less damage because ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Publication of Research on Combination Reovirus and Radiation Therapy 2Rounding up gases, nano-style 2January Market Jitters Fails to Derail Biotech 2January Market Jitters Fails to Derail Biotech 3January Market Jitters Fails to Derail Biotech 4
(Date:9/29/2014)... Advocacy Awards will honor ... medical progress to improve the health and economic ... place on Wednesday, March 11, 2015, at the ... The 2015 Advocacy Award winners are ABC,s "Good ... of the Milken Institute and FasterCures; Dr. Kenneth ...
(Date:9/29/2014)... Energy Joint Genome Institute (DOE JGI), a DOE ... 32 new projects have been selected for the ... lakes to Caribbean waters, and from plant root ... in forested watersheds, the CSP 2015 projects portfolio ... be extracted. , "These projects catalyze JGI,s ...
(Date:9/29/2014)... WASHINGTON, Sept. 29, 2014 Oktoberfest is ... nothing worse than reaching for a cold ... your beer,s been skunked: chemicals have reacted ... bitter taste. This week, Reactions explains why ... do to keep your brews from going ...
Breaking Biology News(10 mins):Research!America to honor leaders in medical and health research advocacy 2Research!America to honor leaders in medical and health research advocacy 3Research!America to honor leaders in medical and health research advocacy 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 22015 DOE JGI's science portfolio delves deeper into the Earth's data mine 32015 DOE JGI's science portfolio delves deeper into the Earth's data mine 42015 DOE JGI's science portfolio delves deeper into the Earth's data mine 52015 DOE JGI's science portfolio delves deeper into the Earth's data mine 62015 DOE JGI's science portfolio delves deeper into the Earth's data mine 72015 DOE JGI's science portfolio delves deeper into the Earth's data mine 82015 DOE JGI's science portfolio delves deeper into the Earth's data mine 9
... by the University of Zaragoza (UNIZAR) started to carry out ... then they have focused on analysing the fossil remains of ... the Cantabrian region over the past 41,000 years, at the ... conservation status of the fossils have enabled the researchers to ...
... in <A HREF=",http://chinese.eurekalert.org/zh/emb_releases/2009-06/kcl-nss060209.php,">Chinese . Flooding is ... globe. It is the worst natural disaster in the ... figure is expected to increase to 3.5 billion over ... that took place in China over the past decade ...
... In recent years, obesity has taken on epidemic proportions ... early death and rising health care costs. According to ... a quarter of all American adults and more than ... While recent research advances and treatment ...
Cached Biology News:Cantabrian cornice has experienced seven cooling and warming phases over past 41,000 years 2Next-generation software system for flood warning and risk analysis to be developed 2Researchers engineer metabolic pathway in mice to prevent diet-induced obesity 2Researchers engineer metabolic pathway in mice to prevent diet-induced obesity 3
... new MALDI O-TOF creates a new category ... orthogonal platform that has been licensed to ... of Manitoba. , As the first single ... and collisional cooling, the prOTOF 2000 represents ...
Rat Dermal Fibroblasts (RDF) (>500,000 cells)...
...
... The NeuroLog System is a compact, versatile & ... variety of purposes including: Intracellular, Extracellular, Transducer ... The NeuroLog Case & Power Supply unit ... Modules are not only powered by this ...
Biology Products: